JPS62201570A - Preparation of dried cell of survival bifidus bacteria - Google Patents
Preparation of dried cell of survival bifidus bacteriaInfo
- Publication number
- JPS62201570A JPS62201570A JP61034121A JP3412186A JPS62201570A JP S62201570 A JPS62201570 A JP S62201570A JP 61034121 A JP61034121 A JP 61034121A JP 3412186 A JP3412186 A JP 3412186A JP S62201570 A JPS62201570 A JP S62201570A
- Authority
- JP
- Japan
- Prior art keywords
- sod
- survival
- bacterial cells
- bifidus bacteria
- bifidobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000894006 Bacteria Species 0.000 title abstract description 18
- 230000004083 survival effect Effects 0.000 title abstract description 7
- 238000002360 preparation method Methods 0.000 title description 2
- 230000001580 bacterial effect Effects 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 claims abstract 4
- 108010012715 Superoxide dismutase Proteins 0.000 claims abstract 4
- 241000186000 Bifidobacterium Species 0.000 claims description 20
- 238000001035 drying Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 241001608472 Bifidobacterium longum Species 0.000 abstract description 5
- 229940009291 bifidobacterium longum Drugs 0.000 abstract description 5
- 238000004108 freeze drying Methods 0.000 abstract description 4
- 235000013618 yogurt Nutrition 0.000 abstract description 2
- 241000607715 Serratia marcescens Species 0.000 abstract 1
- 238000000034 method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000003860 storage Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003223 protective agent Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000186016 Bifidobacterium bifidum Species 0.000 description 4
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 4
- 235000013923 monosodium glutamate Nutrition 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229940073490 sodium glutamate Drugs 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001655328 Bifidobacteriales Species 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- -1 Lipid peroxide Chemical class 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000223261 Trichoderma viride Species 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Landscapes
- Dairy Products (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は、生残性ビフィズス菌乾燥菌体製造法に係り、
偏性嫌気性ビフィズス菌の生菌数を長時間に互って維持
する乾燥菌体のS8!造法に関するものである。Detailed Description of the Invention (Industrial Application Field) The present invention relates to a method for producing dried viable bifidobacteria cells,
S8, a dried bacterial cell that maintains the viable number of obligate anaerobic bifidobacteria for a long time! It is related to the method of construction.
(従来の技術)
ビフィズス菌(ビフィドバクテリウム属)はj腸内の腐
敗を抑制し、有害物質の生成を防ぎ、また、腸内に発生
した有害物質の体内吸収を防ぐ等の整腸効果を有する有
用菌で、その有効性が立証されつつある。(Prior art) Bifidobacterium (Bifidobacterium genus) has intestinal regulation effects such as suppressing putrefaction in the intestines, preventing the production of harmful substances, and preventing the absorption of harmful substances generated in the intestines. It is a useful bacterium that has the following properties, and its effectiveness is being proven.
このため、最近はとフイズス菌を含有させた牛乳、ヨー
グルト等の飲料、成るいはとフイズス菌の乾燥菌体製剤
が市販され、健康維持増進を目的として広く利用される
ようになった。For this reason, recently, beverages such as milk and yogurt containing F. fudus bacteria, or dried bacterial cell preparations of F. fudus bacteria, have become commercially available and are widely used for the purpose of maintaining and promoting health.
しかるに偏性嫌気性范であるビフィズス葭は酸素の存在
下で非常に不安定で、培養基調製、接種、培養、乾燥、
まで可及的に空気に触れないよう1こ常に吐い酸化還元
電位を保持し、保持中も脱気、遮光、低温などの保存条
件をきびしく制御しているに拘わらず、乾燥菌体は保存
中に死滅し易く、一定の生菌数を長時間にわたって維持
することは益だ困難である。However, Bifidus lily, which is an obligate anaerobic plant, is extremely unstable in the presence of oxygen, and requires culture medium preparation, inoculation, cultivation, drying,
Dried bacterial cells are preserved during storage, even though storage conditions such as deaeration, light shielding, and low temperature are strictly controlled during storage, and storage conditions such as deaeration, light shielding, and low temperature are strictly controlled. It is extremely difficult to maintain a constant number of viable bacteria over a long period of time.
その困難性は酸素が嫌気性の該ビフィズス菌に対して毒
性に働くによるとされ、その酸化メカニズムにカタラー
ゼ説、スーパーオキシドアニオン(02−>説などがあ
るが、定説はない9他方、近年スーパーオキシドディス
ムターゼ(以下SODと略称する)を食品の酸化性物質
の自動酸化抑制(特公昭58−13147号公報参照)
、化粧料組成物の一成分として皮膚への色素沈着抑制(
特開昭55−87712号公報参照)、リューマチや関
節炎における抗炎症剤、放射線障害の治療(特開昭51
−63984号公報、特開昭58−16685号公報参
照)等に使用する文献があり、又各種の糸状菌を固体培
地に培養してSODを工業的に生産する方法(特開昭5
7−36984号公報参照)や、ヒト由来のSODを効
率的に精製する方法(特開昭58−1s:+o9x号公
報参照)や、SODの安定性を増加させる方法(特開昭
58−32826号公報参照)など、種々の知見が公開
されている。The difficulty is said to be due to the toxic effect of oxygen on the anaerobic bifidobacteria.The oxidation mechanism includes the catalase theory and the superoxide anion (02-> theory), but there is no established theory.9On the other hand, in recent years superoxide Oxide dismutase (hereinafter abbreviated as SOD) is used to inhibit autoxidation of oxidizing substances in foods (see Japanese Patent Publication No. 13147/1983)
, suppressing pigmentation on the skin as a component of cosmetic compositions (
JP-A No. 55-87712), anti-inflammatory agents for rheumatism and arthritis, and treatment of radiation damage (see JP-A-55-87712)
-63984, Japanese Patent Application Laid-Open No. 16685/1982), and a method for industrially producing SOD by culturing various filamentous fungi on a solid medium (Japanese Patent Laid-Open No. 58-16685).
7-36984), a method for efficiently purifying human-derived SOD (see JP-A-58-1S:+o9x), and a method for increasing the stability of SOD (JP-A-58-32826). A variety of findings have been published, including the following:
しかしながら、ビフィズス菌のごとき嫌気性菌の生残促
進に関してSODを使用することは、従来提案されたこ
とが全くない。However, the use of SOD to promote the survival of anaerobic bacteria such as bifidobacteria has never been proposed.
(発明が解決しようとする問題点)
ビフィズス菌乾燥菌体の保存中に生ずる生菌死滅の化学
的メカニズムが明らかにされていることは、既に述べた
通りである。本発明はこの既知のメカニズムを前提にし
て保存性改善を見い出す事を最大の問題点とするもので
ある。(Problems to be Solved by the Invention) As mentioned above, the chemical mechanism of killing viable bacteria that occurs during storage of dried Bifidobacterium cells has been clarified. The main problem of the present invention is to find an improvement in storage stability based on this known mechanism.
(問題点を解決するための手段)
本発明は前項に述べた問題点を解決することを目的とす
るものである。本発明者らはこの目的実現のために研究
を重ねていたが、SODの添加が極く有用なことを知見
してさらに研究を重ね、ビフィズス菌の培養時、あるい
は培養後の菌体含有液にSODを添加し、乾燥凍結する
ことを開発した。(Means for Solving the Problems) The present invention aims to solve the problems described in the previous section. The inventors of the present invention have conducted repeated research to realize this objective, and upon discovering that the addition of SOD is extremely useful, they have conducted further research and discovered that the addition of SOD is extremely useful. We have developed a method of adding SOD to and drying and freezing.
即ち、ビフィズス菌の培養において、通常用いられる培
養基にSODを無菌的に加えて、常法の嫌気条件で培養
を9〒うか、SODを加えずして得られた菌体含有液に
、SODを無菌的に添加した後、遠心分離により集菌し
、これに脱脂粉乳や、グルタミン酸ナトリウムなどから
なる公知の保護剤を加えて、凍結÷l燥して得られる生
残性の高いビフィズス菌乾燥菌体の製造法であって、S
ODの起源は動物、植物、微生物等の生物中に分布して
いる何れがのものでよい。しかし大量生産の見地からは
、工業生産が比較的容易で経済的に有利な微生物起源の
、例えばアスペルギルス属、リゾープス属、トリコデル
マ属、又はセラチア属から得られるものが好ましい。That is, in the culture of bifidobacteria, SOD is added aseptically to a commonly used culture medium and cultured under anaerobic conditions in a conventional manner for 9 days, or SOD is added to a solution containing bacterial cells obtained without adding SOD. After adding aseptically, collect the bacteria by centrifugation, add skim milk powder or a known protective agent such as monosodium glutamate, and freeze/dry to obtain highly viable Bifidobacterium desiccated bacteria. A method for manufacturing a body, comprising:
The origin of OD may be any source distributed in living organisms such as animals, plants, and microorganisms. However, from the standpoint of mass production, those obtained from microbial sources that are relatively easy to industrially produce and are economically advantageous, such as those from the genus Aspergillus, Rhizopus, Trichoderma, or Serratia, are preferred.
(効果)
本発明の効果を、SOD力価測定、及び生菌数測定によ
り確認した。(Effect) The effect of the present invention was confirmed by SOD titer measurement and viable cell count measurement.
SOD力価測定法は、02−の生成量を定量する公知の
方法であるニトロブルーテトラゾリウム(NBT)のホ
ルマザンへの還元反応で行った。(文献二金田尚志、植
田伸夫、過酸化脂質実験法p141〜14G、医歯薬出
版゛83)
即ち、このSOD力価測定法の具体的方法は、複数の試
験管のそれぞれに、0.05M炭酸ナトリウム緩衝液(
1)1110.2)の2.4+nN、0.75M f’
J B Tの0.1+oJ、3、(hMキサンチンの0
.1+aN、3.0mM エチレンノアミン四酢酸ナト
リウムの0.1ml、 0.15%ウシ血清アルブミン
の0.1+aL及び適量のSODを含む試料溶液(対照
試験管にはSODを含まない緩衝液)の0、1mj’を
加え、25℃に10分間保った後、キサンチンオキシタ
ーゼ01 、 m(!を加えて反応を開始する。20分
後に60m M塩化銅0.11を加えて反応を停止し、
5601616におけるOD値を測定する。The SOD titer was measured using a reduction reaction of nitroblue tetrazolium (NBT) to formazan, which is a known method for quantifying the amount of 02- produced. (Reference Hisashi Nikaneda, Nobuo Ueda, Lipid peroxide experimental method p141-14G, Ishiyaku Publishing 83) That is, the specific method of this SOD titer measurement method is to add 0.05M to each of multiple test tubes. Sodium carbonate buffer (
1) 2.4+nN of 1110.2), 0.75M f'
J B T 0.1 + oJ, 3, (hM xanthine 0
.. 1+aN, 0.1ml of 3.0mM sodium ethylenenoaminetetraacetate, 0.1+aL of 0.15% bovine serum albumin, and a sample solution containing the appropriate amount of SOD (buffer without SOD in control tubes). , 1mj' and kept at 25°C for 10 minutes, xanthine oxidase 01, m(!) was added to start the reaction. After 20 minutes, 60mM copper chloride 0.11 was added to stop the reaction.
Measure the OD value at 5601616.
対照におけるOD値の増加を、20分間に50%抑制し
たSOD活性を一単位とした。The SOD activity that suppressed the increase in OD value in the control by 50% in 20 minutes was defined as one unit.
別表は、本発明者らが通常の培養条件で得た微生物起源
酵素剤のSOD活性を例示したものである。The attached table exemplifies the SOD activity of microbial-derived enzyme preparations obtained by the present inventors under normal culture conditions.
別 表 (注)菌株は全部出願人会社の保存菌株である。Separate table (Note) All strains are archived strains of the applicant company.
生菌数測定法はBL菌体を光間(文献:臨床検査18巻
p1163、“74)の希釈液で段階的に希釈後、0.
1162を市販のBL寒天平板培地上にコンラーノ枠で
塗布し、37℃、48時間嫌気培養し、その培養後生じ
たコロニーを数え、希釈倍数を乗じてサンプル当りの生
菌数を算出する方法を採った。The method for measuring the number of viable bacteria is to dilute BL bacteria in stages with the diluent of Hikama (Reference: Clinical Examination Vol. 18, p. 1163, "74"), and then dilute the BL cells to 0.
1162 was spread on a commercially available BL agar plate medium in a Conrano frame, cultured anaerobically at 37°C for 48 hours, and the colonies formed after the culture were counted and multiplied by the dilution factor to calculate the number of viable bacteria per sample. I took it.
本発明法は複数のビフィズス菌体について多くの実施例
を有し、生菌の保有数についても実施例毎に異なる。よ
って次項に実施例(1)・〜(5)を示すと共に、第1
表〜第5表に前記測定法によった生菌数を示した。The method of the present invention has many examples using a plurality of Bifidobacterial cells, and the number of viable bacteria retained varies from example to example. Therefore, Examples (1) to (5) are shown in the next section, and the first
Tables 5 to 5 show the number of viable bacteria determined by the above measurement method.
(実施例)
o f51実施例
脱脂粉乳7%、イーストエキス0.5%、ライ−ン80
0.05%、L−シス?イン0.05%などを含むビ
フィズス菌の培養において、通常用いられる液体培養液
2gを加熱滅菌冷却後別表(前出)のセラチア・マルセ
ンスのSODを対培養液0.24%(50U/+ne)
添加し、これにビフィドバクテリウム・ロンガム(^T
CC15707)を接種し、培養中10%Na2CO,
を添加してI’11を6.5以上に維持し、CO2がス
、N2ガスを通じながら37°C18時間の嫌気培養を
行い、培養終了後、遠心分離により菌体を濃縮すると共
に、嫌気性菌の凍結乾燥に際して通常使用されている公
知の保護剤カゼイン12%、乳I!20%、グルタミン
酸ナトリウム2%、を含む溶液300mJを用い、(文
献:根井外喜男;徽生物の保存性p212東京大学出版
会1978年)コレに別表(’M 出)のセラチア・マ
ルセッセンスの5OD60.24%と前記の菌体濃縮液
6o「III!ヲjM L テ、常法により凍結乾燥を
施した。(Example) o f51 Example Skim milk powder 7%, Yeast extract 0.5%, Line 80
0.05%, L-cis? In the culture of Bifidobacterium containing 0.05% ne, etc., 2 g of the liquid culture solution normally used is heat sterilized and cooled, and then the SOD of Serratia marsens in the attached table (mentioned above) is added to the culture solution at 0.24% (50 U/+ne).
Bifidobacterium longum (^T
CC15707) was inoculated and cultured with 10% Na2CO,
was added to maintain I'11 at 6.5 or higher, and anaerobic culture was performed at 37°C for 18 hours while passing CO2 and N2 gas. After the culture was completed, the bacterial cells were concentrated by centrifugation, and the anaerobic Casein 12%, milk I!, a well-known protective agent commonly used during freeze-drying of bacteria. Using 300 mJ of a solution containing 20% sodium glutamate and 2% sodium glutamate, the 5OD60. 24% and the above-mentioned bacterial cell concentrate 60% was freeze-dried by a conventional method.
以上により得られた乾燥菌体の重量は約1108であり
、第1表に示すように明らかに生残性が高い乾燥菌体が
得られた。The weight of the dried bacterial cells obtained as described above was about 1108, and as shown in Table 1, dried bacterial cells with clearly high survivability were obtained.
◎ 第2実施例
tjS1実施例において使用した組成の液体培養液2e
にSODを添加することなくビフィドバクテリウム・ロ
ンガム^TCC15707を接種しで、第1実施例と同
様に嫌気培養し、培養終了後直ちに別表(前出)のトリ
コデルマ・ビリデのSODを曲記培養液に対して0.1
4%(50υ/1trlり添加し、遠心分離により菌体
を濃縮して、この濃縮菌体60+ojを第1実施例と同
じ組成の保護剤溶液300m1!に加え、更に別表のト
リコデルマ・ビリデのSODを対10.14%添加し、
常法によって凍結乾燥を行った。◎ Second Example tj Liquid culture solution 2e with the composition used in Example S1
Bifidobacterium longum ^TCC15707 was inoculated without adding SOD to the cells, and cultured anaerobically in the same manner as in the first example. 0.1 for liquid
4% (50υ/1trl) was added, the bacterial cells were concentrated by centrifugation, 60+oj of the concentrated bacterial cells were added to 300ml of a protectant solution with the same composition as in the first example, and the SOD of Trichoderma viride in the attached table was added. Added 10.14% of
Freeze-drying was performed by a conventional method.
以上により得た乾燥菌体の重量は約110gであって、
第2表に示すように明らかに生残性の優れた乾燥菌体が
得られた。The weight of the dried bacterial cells obtained above was about 110 g,
As shown in Table 2, dried bacterial cells with clearly excellent survivability were obtained.
◎ 13実施例
乳糖0.2%、ペプトン1.0%、酵母エキス1.0%
、肉エキス0.5%、ツイーン800.1%、システィ
ン0.05%などを含むビフィズス菌用として通常用い
られている液体培養液22を滅菌冷却後、これに別表(
前出)のりゾープス・オリーゼのSODを対培養液0.
33%(50υ/111Fり添加し、ビフィドバクテリ
ウム・ビフイグムへTCC11146を接種して、培養
中は10%N arc O−でPII6.5以上に維持
し、CO2ガス、N2ガスを通じながら35℃、10時
間の嫌気培養を行い、培養終了後直ちに遠心分離により
菌体を濃縮し、保護剤として脱皿粉乳25%、デンプン
分解物1096、グルタミン酸ナトリウム1%を含む溶
8!300+nl!を用い、これに前記のビフィズス濃
縮液60m1と別表(前出)のりゾープスオリーゼSO
Dを対液0.33%添加し、常法により凍結乾燥を行っ
た。◎ Example 13 Lactose 0.2%, peptone 1.0%, yeast extract 1.0%
After sterilizing and cooling the liquid culture solution 22, which is commonly used for bifidobacteria and contains meat extract 0.5%, Tween 800.1%, cysteine 0.05%, etc., it is shown in the attached table (
(mentioned above) The SOD of Norizopus oryzae was set to 0.
33% (50υ/111F) was added to inoculate Bifidobacterium bifigum with TCC11146, and during cultivation, the PII was maintained at 6.5 or higher with 10% N arc O-, and the temperature was maintained at 35°C while passing CO2 gas and N2 gas. , conduct anaerobic culture for 10 hours, concentrate the bacterial cells by centrifugation immediately after the completion of culture, and use 8!300+nl! of solution containing 25% of deflated milk powder, 1096 starch decomposition products, and 1% sodium glutamate as a protective agent. Add to this 60 ml of the above bifidus concentrate and Zops Oryze SO
0.33% of D was added to the liquid, and freeze-drying was performed by a conventional method.
以上により得られた乾燥菌体の重量は約110gで、第
3表に示すように明らかに生残安定性の良好な乾燥菌体
が得られた。The weight of the dried bacterial cells obtained in the above manner was approximately 110 g, and as shown in Table 3, dried bacterial cells with clearly good survival stability were obtained.
◎ 第4実施例
第3実施例においで使用した組成の液体培養液 2f!
にSODを添加することなくビフィドバクテリウム・ビ
フィダムATCC11146を接種して嫌気培養を行い
、培養終了後別表(11り出)のアスペルギルス・二I
f−8OD ’eH培養液 6%(’1017/1a
e)添加し、遠心分離により菌体を濃縮すると共に、こ
の菌体濃縮液60mff1::第3実施例と同じm戒の
保護剤溶液300 +n lを添加し、常法により凍結
乾燥した。◎ Fourth Example Liquid culture solution with the composition used in the third example 2f!
was inoculated with Bifidobacterium bifidum ATCC 11146 without adding SOD and cultured anaerobically.
f-8OD 'eH culture solution 6% ('1017/1a
e) was added, and the bacterial cells were concentrated by centrifugation, and 60 mff1 of this bacterial cell concentrate: 300 + nl of the same protective agent solution as in the third example was added, and freeze-dried by a conventional method.
以上により得られた乾燥菌体の重量は約110gで、第
4表に示すように明らかに生残安定性が高し1乾燥菌体
が得られた。The weight of the dried bacterial cells obtained in the above manner was about 110 g, and as shown in Table 4, the survival stability was clearly high, and one dried bacterial cell was obtained.
◎ 第5実施例
第4実施例と同様にSODを添加しないで、ビフィドバ
クテリウム・ビフィダムΔTCC11146を接種して
嫌気培養後、遠心分離を行って菌体を濃縮し、この菌体
濃縮液60 +n eに第3実施例と同じ組成の保護剤
溶液300 +n lを混合し、別表(前出)のりゾー
プス・デレマSODを対混合液4.1%(90υ/ 1
61! )添加し、常法により凍結乾燥した。◎ Fifth Example As in the fourth example, without adding SOD, Bifidobacterium bifidum ΔTCC11146 was inoculated, cultured anaerobically, and centrifuged to concentrate the bacterial cells. +n e was mixed with 300 + n l of a protective agent solution having the same composition as in the third example, and 4.1% of the mixed solution (90 υ / 1
61! ) and freeze-dried by a conventional method.
以上により得られた乾燥菌体の重量は約1108で、第
5表に示すように明らかに生残安定性のすぐれた乾燥菌
体を得られた。The weight of the dried bacterial cells obtained in the above manner was approximately 1108, and as shown in Table 5, dried bacterial cells with clearly excellent survival stability were obtained.
第1表:ビフィドバクテリウム・ロンがム^TCC15
707の生菌数第2表:ビフィドバクテリウム・ロンガ
ム^TCC15707の生菌数第3表:ビフィドバクテ
リウム・ビフィダム^TCC1114Gの生菌数第4表
:ビフィドバクテリウム・ビフィダム^TCC1114
6の生菌数第5表:ビフイドバクテリウム・ビフィダム
ATCC11146の生菌数出願人 新日本化学工業株
式会社
手続補正書
昭和61年2月20日
3、補正をする者
事件との関係 出願人
4、代理人
住 所 名古屋市中村区椿町15番19号大正生命ビル
6、補正により増加する発明の数
7.11Il正の対象 明細書
8、補正の内容 別紙の通り
昭和61年2月18日付提出の特許願
補 正 の 内 容
1、 明細8第9′r1第2行と第3行の間に次の通り
に加入する。Table 1: Bifidobacterium longum ^TCC15
707 viable count Table 2: Bifidobacterium longum^TCC15707 viable count Table 3: Bifidobacterium bifidum^TCC1114G viable count Table 4: Bifidobacterium bifidum^TCC1114
6 Viable Bacteria Count Table 5: Bifidobacterium Bifidum ATCC 11146 Viable Bacterial Count Applicant Shin Nippon Chemical Co., Ltd. Procedure Amendment Date February 20, 1986 3. Relationship with the person making the amendment case Applicant 4. Address of the agent: Taisho Seimei Building 6, 15-19 Tsubaki-cho, Nakamura-ku, Nagoya City Number of inventions increased by the amendment 7.11 Il Correction subject Description 8. Contents of the amendment February 18, 1988 as attached Contents 1 of the amendment to the patent application submitted on the date, Part 8, No. 9'r1, lines 2 and 3, the following is added:
[本発明に使用するビフィズス菌は例えばビフィドバク
テリウム・ロンガム(B 、 Iongum)、ビフィ
ドバクテリウム・インファンナイス(B、1nfanL
is)、ビフィドバクテリウム・ブリーベ(B、bre
ve)、ビフィドバクテリウム・ビフィダム(B、bi
fiduIll)など、とフィトバクテリウムに属する
菌株であればいずれでもよい。[Bifidobacteria used in the present invention include, for example, Bifidobacterium longum (B, Iongum), Bifidobacterium infantis (B, 1nfanL)
is), Bifidobacterium breve (B, bre
ve), Bifidobacterium bifidum (B, bi
Any strain belonging to Phytobacterium may be used.
これらのビフィズス菌の培養菌体含有液に対するSOD
の有効添加量はSOD生成起源に関係なく、10u /
ml!tイL500t/ /mlテア;4fy’lil
済性及び香味性の観点から考慮して30υ/1ml!な
いし100 Ll / ml!程度が望ましい。」以
上
手続補正書
昭和62年3月24日
特許庁長官 殿 1 で(′+
1□
1、事件の表示 rf1昭61−34121、発明の名
称 生残性ビフィズス菌乾燥菌体製造法3.1’ll正
をする者 出願人
事件との関係
名 称 新日本化学工業株式会社
4、代理人
7、補正の対象 明a+g
8、補正の内容 別紙の通り。SOD of these Bifidobacterium culture cells
The effective amount of addition is 10u/ regardless of the origin of SOD generation.
ml! tI L500t/ /ml tear; 4fy'lil
30υ/1ml in consideration of quality and flavor! Or 100 Ll/ml! degree is desirable. ” or later
Written amendment of the above procedure dated March 24, 1986, Mr. Commissioner of the Patent Office, 1 ('+
1□ 1. Indication of the case rf1 1986-34121, Title of the invention Method for producing dried viable bifidobacterium cells 3.1'll Person who makes the correction Name of relationship to the applicant case Title Shin Nippon Chemical Industry Co., Ltd. 4 , Agent 7, Subject of amendment Akira+g 8, Contents of amendment As attached.
特願昭61−34121
補正の内容
1、 明m書17頁第9行〜第11行に「オキシクーゼ
01.mJ・・・を測定する。」とあるを「オキシター
ゼ0.1J’を加えて反応を開始する。Japanese Patent Application No. 1983-34121 Amendment Contents 1, page 17, lines 9 to 11 of the Memorandum, the text "Measure 01.mJ of oxidase..." was replaced with "Add 0.1J' of oxidase and react. Start.
20分後に60+aM塩化銅0.1meを加えて反応を
停止し、560nmにおけるOD値を測定する。」と訂
正する。After 20 minutes, 0.1 me of 60+aM copper chloride is added to stop the reaction, and the OD value at 560 nm is measured. ” he corrected.
2、 明#I書第9頁第14行に「セラチア・マルセン
ス」とあるを
「セラチア・マルセノセンス」
と訂正する。2. In Book #I, page 9, line 14, the text ``Serratia marcescens'' is corrected to ``Serratia marcenscens''.
3、 明細書110頁第11↑了1こ「S OD 60
.24%」とあるを
「s OD 0.24%」
と訂正する。3. Specification page 110 No. 11↑Ryo 1ko “S OD 60
.. 24%" should be corrected to "s OD 0.24%."
以 上that's all
Claims (1)
ーパーオキシドディスムターゼを添加し、乾燥凍結する
ことを特徴とする生残性ビフィズス菌乾燥菌体製造法。A method for producing dried bacterial cells of viable bifidobacteria, which comprises adding superoxide dismutase to a liquid containing bacterial cells during or after culturing bifidobacteria, and drying and freezing the mixture.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61034121A JPS62201570A (en) | 1986-02-18 | 1986-02-18 | Preparation of dried cell of survival bifidus bacteria |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61034121A JPS62201570A (en) | 1986-02-18 | 1986-02-18 | Preparation of dried cell of survival bifidus bacteria |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS62201570A true JPS62201570A (en) | 1987-09-05 |
JPH0436677B2 JPH0436677B2 (en) | 1992-06-16 |
Family
ID=12405419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61034121A Granted JPS62201570A (en) | 1986-02-18 | 1986-02-18 | Preparation of dried cell of survival bifidus bacteria |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS62201570A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0649603A1 (en) * | 1993-05-11 | 1995-04-26 | Otsuka Pharmaceutical Co., Ltd. | Antioxidant food, antioxidant preparation and antioxidization method |
-
1986
- 1986-02-18 JP JP61034121A patent/JPS62201570A/en active Granted
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0649603A1 (en) * | 1993-05-11 | 1995-04-26 | Otsuka Pharmaceutical Co., Ltd. | Antioxidant food, antioxidant preparation and antioxidization method |
EP0649603A4 (en) * | 1993-05-11 | 1995-10-25 | Otsuka Pharma Co Ltd | Antioxidant food, antioxidant preparation and antioxidization method. |
US6228358B1 (en) * | 1993-05-11 | 2001-05-08 | Otsuka Pharmaceutical Co., Ltd. | Method of producing fermented milk containing manganese and tea |
US6884415B2 (en) | 1993-05-11 | 2005-04-26 | Otsuka Pharmaceutical Co., Ltd. | Antioxidation food product, antioxidation preparation and antioxidation method |
Also Published As
Publication number | Publication date |
---|---|
JPH0436677B2 (en) | 1992-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101355266B1 (en) | A food containing a probiotic and an isolated betaglucan and methods of use thereof | |
Sajedinejad et al. | Lactobacillus salivarius NK02: a potent probiotic for clinical application in mouthwash | |
Edel et al. | Comparative studies on the isolation of “sublethally injured” salmonellae in nine European laboratories | |
USRE40023E1 (en) | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use | |
RU2061392C1 (en) | Method of kvass producing | |
Garvie et al. | The effect of yoghurt on some components of the gut microflora and on the metabolism of lactose in the rat | |
KR20010072540A (en) | Food or drink product with a disinfection property of helicobacter pylori | |
JPH0153035B2 (en) | ||
Tanner et al. | The genus Wolinella | |
RU2352628C2 (en) | Novel strains of bifidobacteria, possessing ability to pruduce glutamine | |
Norin et al. | Establishment of Lactobacillus and Bifidobacterium species in germfree mice and their influence on some microflora-associated characteristics | |
Hoover et al. | Survival of bacteria from human dental plaque under various transport conditions | |
Wang et al. | Cytoprotective effect of Streptococcus thermophilus against oxidative stress mediated by a novel peroxidase (EfeB) | |
JPS62201570A (en) | Preparation of dried cell of survival bifidus bacteria | |
Andersen et al. | Characterization of Neisseria elongata subsp. glycolytica isolates obtained from human wound specimens and blood cultures | |
JP4382295B2 (en) | Urease inactivating composition and food and drink | |
Chierici et al. | Experimental milk formulae with reduced protein content and desialylated milk proteins: influence on the faecal flora and the growth of term newborn infants | |
QUIE | Chronic granulomatous disease of childhood: a saga of discovery and understanding | |
Yamani et al. | Microbial quality of hoummos (chickpea dip) commercially produced in Jordan | |
Margolles et al. | Phenotypic characterization of Listeria monocytogenes and Listeria innocua strains isolated from short-ripened cheeses | |
US20030077255A1 (en) | Compositions of bacteria and alpha-lactalbumin and uses thereof | |
JP2002306125A (en) | Probiotic-containing nutrient composition for infant in packed container | |
WO1989000425A1 (en) | Lipid peroxide content reducer | |
Saddiq | Potential effect of natural musk and probiotic on some pathogens strain | |
JPS59220191A (en) | Noncariogenic composition and drink |